


AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently Amended) A compound of the formula:



wherein:

X is —O, —CH₂, —CH(C₁₋₄ alkyl), —CH(C₃₋₆ cycloalkyl), —S, [[—]]arylene, or [[—]]arylalkylene;

R is —H, [[—]]C₁₋₄ alkyl optionally containing one or more heteroatoms selected from O, S, or N in the chain, [[—]]C₃₋₆ cycloalkyl optionally containing one or more heteroatoms selected from O, S, or N in the ring, [[—]]aryl, arylalkyl, or heterocycle;

Y is —H, [[—]]C₁₋₄ alkyl, or [[—]]C₃₋₆ cycloalkyl;

Z is [[—]]C₁₋₄ alkyl, or [[—]]C₃₋₆ cycloalkyl;

R₁, R₂, R₃, R₄, and R₅ are each independently [[is]] —H, [[—]]C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, —aryl), or —SW, [[(O)]wherein W is —H, —CH₃, or [[—]]aryl[[]]];

~~R₁ is —H, —C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, —aryl), —SW (wherein W is —H, —CH₃, —aryl);~~

~~R₂ is —H, —C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, —aryl), —SW (wherein W is —H, —CH₃, —aryl);~~

~~R₃ is —H, —C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, —aryl), —SW (wherein W is —H, —CH₃, —aryl);~~

~~R₄ is —H, —C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, —aryl), —SW (wherein W is —H, —CH₃, —aryl); and~~

R₁ and R₂ are optionally CH=CH-CH=CH;
or a pharmaceutically acceptable salt thereof.

2. (Canceled).

3. (Currently Amended) ~~[[A]] The compound of having formula A as claimed in~~
claim 1, wherein

X = S	Y = H	Z = CH ₃	R = <i>i</i> Pr	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = CH ₃	R = Pen	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = Et	R = <i>i</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = Et	R = <i>i</i> Pen	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = CH ₃	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = CH ₃	R = <i>i</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = CH ₃	R = <i>n</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = CH ₃	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = CH ₃	R = <i>c</i> Pen	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = CH ₃	R = <i>c</i> Es	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = Et	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = Et	R = <i>c</i> Pen	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = CH ₃	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = CH ₃	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = <i>c</i> Pe	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = CH ₃	R = <i>n</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F; or
X = S	Y = CH ₃	Z = CH ₃	R = <i>i</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F.

4. (Canceled).

5. (Currently Amended) A pharmaceutically acceptable salt of ~~[[a]] the~~
compound of claim 1.

6. (Currently Amended) A process for the preparation of a compound ~~of having~~
~~formula A as claimed in claim 1, wherein X = O, comprising the steps of reacting a wherein~~
~~the proper~~ methyl arylacetylalkylacetate ~~is reacted~~ with O-methylisourea in presence of
calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and
reacting the 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil the so obtained 2-O-methyl(5-

~~alkyl)-6-benzyl(substituted)uracils are reacted with a the proper potassium alkoxide according to scheme A.~~

7. (Currently Amended) A process for the preparation of a compound of having formula A as claimed in claim 1, wherein X = S, comprising the steps of reacting a wherein the proper methyl arylacetylalkylacetate is reacted with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil the so obtained 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracils are reacted with a the proper potassium alkoxide according to scheme B.

8. (Canceled).

9. (Currently Amended) A method of treating infection by HIV or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of as claimed in claim 1 or a pharmaceutically acceptable salt thereof.


10. (Canceled).

11. (Currently Amended) A pharmaceutical composition comprising a compound of as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. (Currently Amended) A method of treating infection by HIV or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of as claimed in claim 1 or a pharmaceutically acceptable salt thereof, in combination with another anti-HIV agent selected from the group consisting of abacavir, zidovudine, BILA 1906, BILA 2185, BM+51.0836: ~~triazoloisoindolinone derivative~~, BMS 186,318: ~~aminodiol derivative~~ HIV-1 protease inhibitor, d4API, stavudine, efavirenz, HBY097, HEPT, KNI-272, L697,593, L-735,524, L-697,661, L-FDDC, L-FDOC, nevirapine, foscarnet, PMEA, PMPA, Ro 31-8959, RPI-3121, SC-52151, SC-55389A, TIBO R82150, TIBO 82913, TSAO-m3T, U90152, UC[[:]] thiocarboxanilide derivatives[[:]] such as UC-781[[:]] and UC-82, VB 11,328, amprenavir, XM 323, delaviridine, famciclovir, gancyclovir, penciclovir, indinavir, nelfinavir, ritonavir, saquinavir, DDI, DDC, [[D]]delaviridine, β -LddA, β -L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, [[(]]3'-azido-2',3'-dideoxy-5-methyl-cytidine[[D]]],

3'-azido nucleosides, β -D-dioxolane nucleosides such as β -D-dioxolanylguanine (DXG), β -D-dioxolanyl-2,6-diaminopurine (DAPD), and β -D-dioxolanyl-6-chloropurine (ACP), D4T, FTC, 3TC, AZDU, and amprenavir.

13. (Currently Amended) A compound of the formula:



wherein:

X is —O, —CH₂, —CH(C₁₋₄ alkyl), —CH(C₃₋₆ cycloalkyl), —S, ~~[[—]]~~arylene, or ~~[[—]]~~arylalkylene;

R is —H, ~~[[—]]~~C₁₋₄ alkyl optionally containing one or more heteroatoms selected from O, S or N in the chain, ~~[[—]]~~C₃₋₆ cycloalkyl optionally containing one or more heteroatoms selected from O, S or N in the ring, ~~[[—]]~~aryl, arylalkyl, or heterocycle

Y is —H, ~~[[—]]~~C₁₋₄ alkyl, or ~~[[—]]~~C₃₋₆ cycloalkyl;

Z is —H, ~~[[—]]~~C₁₋₄ alkyl, or ~~[[—]]~~C₃₋₆ cycloalkyl;

R₁ is ~~[[—]]~~C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, aryl), or —SW₁ ~~[[()]]~~wherein W is —H, —CH₃, or ~~[[—]]~~aryl~~[[()]]~~;

R₂, R₃, R₄, and R₅ are each independently ~~[[is]]~~ —H, ~~[[—]]~~C₁₋₄ alkyl, halogen, —NO₂, —OW (wherein W is —H, —CH₃, aryl), or —SW₁ ~~[[()]]~~wherein W is —H, —CH₃, or ~~[[—]]~~aryl~~[[()]]~~;

~~R₃ is —H, C₁₋₄ alkyl, halogen, NO₂, OW (wherein W is —H, —CH₃, aryl), SW (wherein W is —H, —CH₃, aryl);~~

~~R₄ is —H, C₁₋₄ alkyl, halogen, NO₂, OW (wherein W is —H, —CH₃, aryl), SW (wherein W is —H, —CH₃, aryl);~~

~~R₅ is —H, C₁₋₄ alkyl, halogen, NO₂, OW (wherein W is —H, —CH₃, aryl), SW (wherein W is —H, —CH₃, aryl); and~~

R₁ and R₂ are optionally CH=CH-CH=CH;
or a pharmaceutically acceptable salt thereof.

14. (Currently Amended) A compound of having formula B as claimed in claim 13, wherein

X = O Y = H Z = H R = *s*Bu R₁ = F R₂ = H R₃ = H R₄ = H R₅ = F; or

X = O Y = H Z = H R = *c*Pen R₁ = F R₂ = H R₃ = H R₄ = H R₅ = F.

15. (Currently Amended) A compound of having formula B as claimed in claim 13, wherein

X = S	Y = H	Z = H	R = <i>s</i> Bu	R ₁ = NO ₂	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = H;
X = S	Y = H	Z = H	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = H;
X = S	Y = H	Z = H	R = CH ₃	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = <i>i</i> Pr	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = <i>n</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = <i>i</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = <i>s</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = <i>c</i> Pen	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = H	Z = H	R = CH ₃	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = <i>n</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = <i>i</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = <i>c</i> Pen	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>s</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = H;
X = S	Y = CH ₃	Z = H	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = H;
X = S	Y = CH ₃	Z = H	R = <i>s</i> Bu	R ₁ = Cl	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = Cl;
X = S	Y = CH ₃	Z = H	R = CH ₃	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>n</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>i</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>s</i> Bu	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = <i>c</i> Pen	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = <i>i</i> Pr	Z = H	R = <i>i</i> Pr	R ₁ = F	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = H	Z = H	R = MeSMe	R ₁ = [[R]]E	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = CH ₃	Z = H	R = MeSMe	R ₁ = [[R]]E	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F;
X = S	Y = Et	Z = H	R = MeSMe	R ₁ = [[R]]E	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F; or
X = S	Y = <i>i</i> Pr	Z = H	R = MeSMe	R ₁ = [[R]]E	R ₂ = H	R ₃ = H	R ₄ = H	R ₅ = F.

16. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 13.

17. (Currently Amended) A process for the preparation of a compound of having formula B as claimed in claim 13, wherein X = O, comprising the steps of reacting a wherein the proper methyl arylacetylalkylacetate is reacted with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the so obtained 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil[[s]] are reacted with a the proper potassium alkoxide according to scheme A.

18. (Currently Amended) A process for the preparation of a compound of having formula B as claimed in claim 13, wherein X = S, comprising the steps of reacting a wherein the proper methyl arylacetylalkylacetate is reacted with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the so obtained 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil[[s]] are reacted with a the proper potassium alkoxide according to scheme B.

19. (Currently Amended) A method of treating infection by HIV[[,]] or of treating AIDS, comprising administering to a mammal an effective amount of a compound of as claimed in claim 13 or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) A pharmaceutical composition comprising a compound of as claimed in claim 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. (Currently Amended) A method of treating infection by HIV or of treating AIDS, comprising administering to a mammal an effective amount of a compound of as claimed in claim 13 or a pharmaceutically acceptable salt thereof, in combination with another anti-HIV agent selected from the group consisting of abacavir, zidovudine, BILA 1906, BILA 2185, BM+51.0836: ~~triazoloisoindolinone derivative~~, BMS 186,318: ~~aminodiol derivative~~ HIV-1 protease inhibitor, d4API, stavudine, efavirenz, HBY097, HEPT, KNI-272, L697,593, L-735,524, L-697,661, L-FDDC, L-FDOC, nevirapine, foscarnet, PMEA, PMPA, Ro 31-8959, RPI-3121, SC-52151, SC-55389A, TIBO R82150, TIBO 82913, TSAO-m3T, U90152, UC[[,:]] thiocarboxanilide derivatives[[,]] such as UC-781[[,]] or UC-82, VB 11,328, amprenavir, XM 323, delaviridine, famciclovir, gancyclovir, penciclovir, indinavir,

nelfinavir, ritonavir, saquinavir, DDI, DDC, Delaviridine, β -LddA, β -L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, [[()]3'-azido-2',3'-dideoxy-5-methyl-cytidine[()]], 3'-azido nucleosides, β -D-dioxolane nucleosides such as β -D-dioxolanylguanine (DXG), β -D-dioxolanyl-2,6-diaminopurine (DAPD), and β -D-dioxolanyl-6-chloropurine (ACP), D4T, FTC, 3TC, AZDU, and amprenavir.

22. (New) The compound of claim 1, wherein R_1 is halo.
23. (New) The compound of claim 1, wherein R_5 is halo.
24. (New) The compound of claim 1, wherein R_1 and R_5 are independently halo.
25. (New) The compound of claim 1, wherein R_1 and R_5 are independently fluoro or chloro.
26. (New) The compound of claim 13, wherein R_1 is halo.
27. (New) The compound of claim 13, wherein R_5 is halo.
28. (New) The compound of claim 13, wherein R_1 and R_5 are independently halo.
29. (New) The compound of claim 13, wherein R_1 and R_5 are independently fluoro or chloro.